COSMOS Pharmaceutical Corporation
3349.T · JPX
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | ¥272,394 | ¥259,122 | ¥246,332 | ¥244,095 |
| % Growth | 5.1% | 5.2% | 0.9% | – |
| Cost of Goods Sold | ¥215,219 | ¥205,049 | ¥193,198 | ¥192,584 |
| Gross Profit | ¥57,175 | ¥54,073 | ¥53,134 | ¥51,511 |
| % Margin | 21% | 20.9% | 21.6% | 21.1% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥0 | ¥107 | ¥0 | ¥0 |
| SG&A Expenses | ¥45,529 | ¥24,506 | ¥41,850 | ¥42,635 |
| Sales & Mktg Exp. | ¥0 | ¥1,561 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥20,791 | ¥0 | ¥112 |
| Operating Expenses | ¥45,529 | ¥45,297 | ¥41,850 | ¥42,747 |
| Operating Income | ¥11,646 | ¥8,776 | ¥11,284 | ¥8,764 |
| % Margin | 4.3% | 3.4% | 4.6% | 3.6% |
| Other Income/Exp. Net | ¥442 | ¥410 | ¥459 | ¥613 |
| Pre-Tax Income | ¥12,088 | ¥9,186 | ¥11,743 | ¥9,377 |
| Tax Expense | ¥3,916 | ¥551 | ¥3,828 | ¥3,092 |
| Net Income | ¥8,171 | ¥8,635 | ¥7,915 | ¥6,285 |
| % Margin | 3% | 3.3% | 3.2% | 2.6% |
| EPS | 103.09 | 108.95 | 99.86 | 79.3 |
| % Growth | -5.4% | 9.1% | 25.9% | – |
| EPS Diluted | 103.09 | 108.95 | 99.86 | 79.3 |
| Weighted Avg Shares Out | 79 | 79 | 79 | 79 |
| Weighted Avg Shares Out Dil | 79 | 79 | 79 | 79 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥27 | ¥12 | ¥14 | ¥11 |
| Interest Expense | ¥110 | ¥109 | ¥48 | ¥48 |
| Depreciation & Amortization | ¥5,748 | ¥6,013 | ¥5,630 | ¥5,293 |
| EBITDA | ¥17,947 | ¥15,306 | ¥17,421 | ¥14,169 |
| % Margin | 6.6% | 5.9% | 7.1% | 5.8% |